インビボCROの世界市場

インビボCROの世界市場は2030年までに72億米ドルに達する

2024年に46億米ドルと推定されるインビボCROの世界市場は、2024年から2030年にかけてCAGR 7.8%で成長し、2030年には72億米ドルに達すると予測されます。本レポートで分析されているセグメントの一つである低分子は、CAGR 9.0%を記録し、分析期間終了時には51億米ドルに達すると予想されています。大型分子セグメントの成長率は、分析期間中CAGR 5.3％と推定されます。

米国市場は12億米ドルと推定される一方、中国はCAGR 12.4％で成長すると予測される

米国のインビボCRO市場は、2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに15億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.6%と予測されています。欧州では、ドイツがCAGR 5.2%で成長すると予測されています。

世界のインビボCRO市場- 主要動向と促進要因のまとめ

インビボCROサービスが医薬品開発において戦略的重要性を増している理由とは？

インビボ医薬品開発業務受託機関（CRO）は、生きた動物モデルを使用する前臨床および初期段階の調査サービスを外部委託することにより、製薬およびバイオテクノロジー産業において重要な役割を果たしています。これらの研究は、ヒト試験に進む前に、薬剤候補の薬物動態、薬力学、有効性、安全性を評価するために不可欠です。規制当局の監視が厳しくなり、医薬品開発コストが上昇する中、スポンサーは、その技術的専門知識、規制に関する知識、科学的厳密性を確保しながらスケジュールを短縮する能力を求めて、in-vivoに特化したCROをますます利用するようになっています。

生物製剤、遺伝子治療薬、個別化医薬品など、治療薬の複雑性が増すにつれ、より高度な動物実験プロトコールが要求されますが、多くの自社施設では十分に対応できません。インビボCROは、カスタマイズされた試験デザイン、特定の疾患適応のための検証済みモデル、高度なイメージングと遠隔測定機能を提供します。遺伝子組み換え動物モデルの管理、毒性試験の実施、治験薬（IND）申請のサポートなどの能力により、前臨床研究パイプラインにおいて不可欠なパートナーとなっています。

テクノロジーと専門化は、どのようにIn-Vivo CROの能力を進化させているのか？

技術革新はインビボ調査サービスの展望を変えつつあり、CROはより高い精度、再現性、複雑な生物学的反応への洞察を提供できるようになっています。MRI、PET、光イメージングなどのリアルタイム・イメージング技術は、疾患の進行や治療への影響を非侵襲的にモニタリングすることを可能にします。高度な遠隔測定システムは、バイタルサイン、行動変化、生理学的パラメーターの連続測定を可能にし、必要な動物数を減らすと同時にデータの質を向上させる。

CROはまた、バイオファーマ企業の進化するニーズを満たすために、がん、自己免疫疾患、希少疾患、中枢神経系病態などの特殊な疾患モデルを含むポートフォリオを拡大しています。ヒト化マウスモデルやトランスジェニック系統の開発により、よりトランスレーショナルな研究が可能になり、動物とヒトの反応のギャップを埋めることができるようになりました。デジタルラボノート、自動データ収集システム、AIベースのデータ解析ツールの統合により、in-vivo研究全体の業務効率と科学的精度がさらに向上しています。

インビボCRO市場の拡大を牽引するセグメントと地域は？

製薬およびバイオテクノロジー企業は、インビボCROサービスの需要を促進している主要な顧客であり、特に社内の研究開発インフラが限られているため、外部パートナーに大きく依存している中規模および新興のバイオテクノロジー企業です。また、トランスレーショナルメディシン、ワクチン開発、希少疾患研究に重点を置く学術研究機関や政府主導の研究機関からの需要も増加しています。腫瘍学と中枢神経系の治療分野は、腫瘍の挙動と神経機能の研究に必要な広範な動物モデル化により、最大の応用分野を占めています。

北米は、強固なバイオ医薬品研究開発エコシステム、確立された規制の枠組み、研究受託インフラの集中によって支えられており、世界のインビボCRO市場を独占しています。欧州は、ドイツ、英国、フランスの旺盛な需要に支えられています。アジア太平洋地域は、中国とインドに牽引される高成長地域として浮上しており、コスト優位性、規制改革、拡大する現地のバイオ医薬品部門がアウトソーシング活動を引き寄せています。さらに、これらの地域では、倫理的な動物実験や医薬品安全性試験実施基準（GLP）の遵守に対する関心が高まっており、現地のCROが世界クライアントの期待に応えるのに役立っています。

インビボCRO市場の成長はいくつかの要因によってもたらされる...

医薬品候補化合物の複雑化により、臨床試験前に安全性と有効性を評価するための高度な動物モデリングが必要になっています。バイオ医薬品企業は、研究開発の固定費を削減し、専門知識を利用し、競合する治療領域でのスケジュールを短縮するために、インビボ試験のアウトソーシングをますます進めています。生物製剤、細胞・遺伝子治療薬、新規デリバリーシステムのパイプラインが拡大しているため、ヒトと同様の反応をシミュレートできる高度なin-vivo機能の必要性がさらに高まっています。

これと並行して、非侵襲的イメージング、遠隔測定、疾患モデルのカスタマイズの進歩は、in-vivo CROの価値提案を強化し、初期段階の意思決定における戦略的パートナーとなっています。特にIND申請においては、十分に文書化され、倫理的に実施された動物実験が規制当局から重視されており、標準化されたGLP準拠のサービスプロバイダーの重要性が引き続き強化されています。さらに、個別化医薬品や希少疾病用医薬品の需要の高まりは、より的を絞った適応性の高いin-vivo試験の必要性を生み出しています。このような複合的な要因によって、インビボCRO市場は、最新の創薬・医薬品開発に不可欠なものとして、着実かつ持続的な成長を遂げています。

セグメント

分子の種類（低分子、高分子）、治療領域（がん、循環器、糖尿病、自己免疫／炎症疾患、感染症、中枢神経系疾患、その他の治療領域）、サービスタイプ（前臨床試験、臨床研究サービス、ラボサービス、コンサルティングサービス、その他のサービスタイプ）

調査対象企業の例（全 39社）

• Biocytogen
• Charles River Laboratories
• Clinipace（Caidya）
• Covance Inc.
• Crown Bioscience
• Eurofins Scientific
• Evotec SE
• GemPharmatech Co., Ltd.
• ICON plc
• IQVIA Inc.
• Janvier Labs
• Labcorp Drug Development
• Parexel International Corporation
• Pharmaceutical Product Development（PPD）
• PsychoGenics Inc.
• Syneos Health
• Taconic Biosciences, Inc.
• The Jackson Laboratory
• Thermo Fisher Scientific Inc.
• WuXi AppTec

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global In-Vivo CRO Market to Reach US$7.2 Billion by 2030

The global market for In-Vivo CRO estimated at US$4.6 Billion in the year 2024, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Small Molecules, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Large Molecules segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 12.4% CAGR

The In-Vivo CRO market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global In-Vivo CRO Market - Key Trends & Drivers Summarized

Why Are In-Vivo CRO Services Gaining Strategic Importance in Drug Development?

In-vivo contract research organizations (CROs) play a critical role in the pharmaceutical and biotechnology industries by providing outsourced preclinical and early-stage research services involving live animal models. These studies are essential to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of drug candidates before progressing to human trials. As regulatory scrutiny and drug development costs rise, sponsors are increasingly turning to specialized in-vivo CROs for their technical expertise, regulatory knowledge, and capacity to accelerate timelines while ensuring scientific rigor.

The rising complexity of therapeutics-including biologics, gene therapies, and personalized medicines-requires more sophisticated animal testing protocols that many in-house facilities cannot adequately support. In-vivo CROs offer customized study designs, validated models for specific disease indications, and advanced imaging and telemetry capabilities. Their ability to manage genetically engineered animal models, conduct toxicology studies, and support investigational new drug (IND) submissions makes them indispensable partners in preclinical research pipelines.

How Are Technology and Specialization Advancing the Capabilities of In-Vivo CROs?

Technological innovation is reshaping the landscape of in-vivo research services, enabling CROs to deliver higher accuracy, reproducibility, and insight into complex biological responses. Real-time imaging technologies such as MRI, PET, and optical imaging allow for non-invasive monitoring of disease progression and therapeutic impact. Advanced telemetry systems enable continuous measurement of vital signs, behavioral changes, and physiological parameters, reducing the number of animals required while improving data quality.

CROs are also expanding their portfolios to include specialized disease models-such as oncology, autoimmune disorders, rare diseases, and CNS pathologies-tailored to meet the evolving needs of biopharma companies. The development of humanized mouse models and transgenic strains has made it possible to conduct more translational research, bridging the gap between animal and human responses. Integration of digital lab notebooks, automated data capture systems, and AI-based data analysis tools is further increasing operational efficiency and scientific accuracy across in-vivo studies.

Which Segments and Regions Are Driving the Expansion of the In-Vivo CRO Market?

Pharmaceutical and biotechnology companies are the primary clients fueling demand for in-vivo CRO services, especially mid-size and emerging biotech firms that rely heavily on external partners due to limited internal R&D infrastructure. Increasing demand is also seen from academic research institutions and government-sponsored initiatives focused on translational medicine, vaccine development, and rare disease research. The oncology and CNS therapeutic areas represent the largest application segments, owing to the extensive animal modeling required to study tumor behavior and neurological functions.

North America dominates the global in-vivo CRO market, supported by a robust biopharmaceutical R&D ecosystem, established regulatory frameworks, and a high concentration of contract research infrastructure. Europe follows closely, with strong demand across Germany, the UK, and France. Asia-Pacific is emerging as a high-growth region, led by China and India, where cost advantages, regulatory reforms, and expanding local biopharma sectors are attracting outsourcing activity. Additionally, growing interest in ethical animal research and adherence to Good Laboratory Practice (GLP) standards in these regions is helping align local CROs with global clients’ expectations.

The Growth in the In-Vivo CRO Market Is Driven by Several Factors…

It is driven by the increasing complexity of drug candidates, which necessitates advanced animal modeling to evaluate safety and efficacy prior to clinical trials. Biopharmaceutical companies are increasingly outsourcing in-vivo studies to reduce fixed R&D costs, access specialized expertise, and accelerate timelines in competitive therapeutic areas. The expanding pipeline of biologics, cell and gene therapies, and novel delivery systems further amplifies the need for sophisticated in-vivo capabilities that can simulate human-like responses.

In parallel, advances in non-invasive imaging, telemetry, and disease model customization are enhancing the value proposition of in-vivo CROs, making them strategic partners in early-stage decision-making. Regulatory emphasis on well-documented, ethically conducted animal studies-especially for IND filings-continues to reinforce the importance of standardized, GLP-compliant service providers. Furthermore, the increasing demand for personalized and orphan drugs is creating a need for more targeted and adaptable in-vivo studies. These combined factors are ensuring steady and sustained growth of the in-vivo CRO market as a critical enabler of modern drug discovery and development.

SCOPE OF STUDY:

The report analyzes the In-Vivo CRO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type of Molecule (Small Molecules, Large Molecules); Therapeutic Area (Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions, Other Therapeutic Areas); Service Type (Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services, Other Service Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• Biocytogen
• Charles River Laboratories
• Clinipace (Caidya)
• Covance Inc.
• Crown Bioscience
• Eurofins Scientific
• Evotec SE
• GemPharmatech Co., Ltd.
• ICON plc
• IQVIA Inc.
• Janvier Labs
• Labcorp Drug Development
• Parexel International Corporation
• Pharmaceutical Product Development (PPD)
• PsychoGenics Inc.
• Syneos Health
• Taconic Biosciences, Inc.
• The Jackson Laboratory
• Thermo Fisher Scientific Inc.
• WuXi AppTec

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • In-Vivo CRO - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Complexity of Preclinical Studies Drives Outsourcing to Specialized In-Vivo CROs
  • Increased Biotech and Pharma R&D Investments Spur Demand for In-Vivo Efficacy and Safety Studies
  • Growth in Oncology and Rare Disease Research Expands Need for Customized Animal Models
  • Regulatory Emphasis on Early Toxicology Screening Strengthens Role of In-Vivo Testing Services
  • Advancements in Imaging and Biomarker Analysis Enhance Precision in In-Vivo Study Design
  • Use of Humanized and Transgenic Animal Models Expands Market Scope for In-Vivo CRO Providers
  • Shift Toward Accelerated Drug Discovery Timelines Boosts Demand for End-to-End In-Vivo Capabilities
  • Collaborative Academic-Industry Research Models Fuel Outsourcing of Specialized In-Vivo Tasks
  • Increased Preclinical Activity in Cell and Gene Therapies Spurs Need for Complex In-Vivo Platforms
  • Integration of Digital Tools and Real-Time Monitoring Enhances Efficiency in In-Vivo Study Execution
  • Rising Demand for GLP-Compliant Facilities Drives Infrastructure Investments in Preclinical CROs
  • Geographic Expansion of CRO Operations Supports Global Trial Consistency and Regulatory Access
  • Growing Focus on Predictive In-Vivo Toxicology Solutions Reduces Late-Stage Clinical Trial Failures
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World In-Vivo CRO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Large Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Preclinical Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Preclinical Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Preclinical Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Clinical Research Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Clinical Research Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Clinical Research Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Laboratory Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Laboratory Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Laboratory Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Consulting Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Consulting Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Consulting Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Service Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Service Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Service Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Autoimmune / Inflammation Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Autoimmune / Inflammation Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Autoimmune / Inflammation Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for CNS Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for CNS Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for CNS Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• JAPAN
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• CHINA
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• EUROPE
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for In-Vivo CRO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for In-Vivo CRO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• FRANCE
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 95: France Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• GERMANY
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 113: Italy Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 122: UK Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 131: Spain Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 140: Russia Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for In-Vivo CRO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for In-Vivo CRO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• AUSTRALIA
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 170: Australia Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• INDIA
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 179: India Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for In-Vivo CRO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for In-Vivo CRO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for In-Vivo CRO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for In-Vivo CRO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 266: Iran Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 275: Israel Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 293: UAE Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• AFRICA
  • In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 311: Africa Recent Past, Current & Future Analysis for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for In-Vivo CRO by Type of Molecule - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for In-Vivo CRO by Type of Molecule - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for In-Vivo CRO by Service Type - Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for In-Vivo CRO by Service Type - Percentage Breakdown of Value Sales for Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services and Other Service Types for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for In-Vivo CRO by Therapeutic Area - Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for In-Vivo CRO by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions and Other Therapeutic Areas for the Years 2015, 2025 & 2030

IV. COMPETITION